Clinical Trial Highlights: Phase III Study in Spotlight

J Parkinsons Dis. 2019;9(1):3-4. doi: 10.3233/JPD-190002.

Authors

Kevin McFarthing¹, Tanya Simuni²

Affiliations

¹ Parkinson's Advocate, Innovation Fixer Ltd, Oxford, UK. kevin(dot)mcfarthing(at)googlemail(dot)com.
² Parkinson's Disease and Movement Disorders Center, Northwestern University Feinberg School of Medicine, Chicago, USA.

PMID: 30741695
DOI: 10.3233/JPD-190002

No abstract available

MeSH terms

Calcium Channel Blockers / administration & dosage
Calcium Channel Blockers / pharmacology*
Clinical Trial Protocols as Topic*
Clinical Trials, Phase III as Topic*
Follow-Up Studies
Humans
Isradipine / administration & dosage
Isradipine / pharmacology*
Multicenter Studies as Topic
Parkinson Disease / drug therapy*
Research Design

Substances

Calcium Channel Blockers
Isradipine

Associated data

ClinicalTrials.gov/NCT02168842